Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01094717 · ClinicalTrials.gov registry record · NA

Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

A NA study, sponsored by University of Utah.

Terminated
Registry status
NA
Development phase
13
Enrollment target

NCT01094717: Clinical Trial NA study, sponsored by University of Utah.

NCT01094717 is a NA study that was terminated before completion, run by University of Utah. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01094717, a NA study, was terminated before completion, sponsored by University of Utah.

TERMINATED
Registry status
NA
Development phase
13 participants
Enrollment target

Study Summary

This is a randomized, double-blind study of excimer (308-nm UVB) laser added to either tazarotene 0.1% gel or acitretin 25 mg daily for plaque psoriasis. The primary objective of this study is to compare the improvement of psoriatic plaques with and without excimer laser (308-nm UVB) treatment, applied in a randomized and blinded fashion, in subjects on acitretin 25 mg or tazarotene gel 0.1% QD.

Primary Outcome

mean % change in the National Psoriasis Foundation (NPF) psoriasis score of the target plaques \[higher percent change in NPF score is consistent with improvement, while higher absolute NPF score is consistent with worse disease, minimum score of 0 (no disease) and maximum score of 30 (worst disease)\]

Interventions

  • DEVICE Excimer laser
  • DRUG Acitretin 25Mg Oral Capsule
  • DRUG Tazarotene 0.1% Gel,Top
  • DEVICE Sham excimer laser

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2010-01
Est. Completion 2011-10
Phase NA
University of Utah

818 total trials

Why NCT01094717 stopped before completion

NCT01094717 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 4 interventions - of which Excimer laser is the first listed.

NCT01094717 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01094717 about?

NCT01094717 is a clinical study titled "Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis". This is a randomized, double-blind study of excimer (308-nm UVB) laser added to either tazarotene 0.1% gel or acitretin 25 mg daily for plaque psoriasis. The primary objective of this study is to compare the improvement of psoriatic plaques with and without excimer laser (308-nm UVB) treatment, app...

What is the current status of trial NCT01094717?

This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2010-01. Estimated completion is 2011-10.

What interventions are being tested in trial NCT01094717?

The interventions under investigation include: Excimer laser (DEVICE), Acitretin 25Mg Oral Capsule (DRUG), Tazarotene 0.1% Gel,Top (DRUG), Sham excimer laser (DEVICE).

Who is sponsoring clinical trial NCT01094717?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01094717's enrollment target sits among peer trials

13 1911th of 2000 higher than 88 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01094717, the US trial registry maintained by the National Library of Medicine. NCT01094717 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.